XENE

Xenon Pharmaceuticals Inc.
CAPPED RATING

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc. (XENE) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (F). The rating has held at D+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.7
EV / EBITDA -6.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -35.1%
Price Return 12M 2.0%
Catalyst Signal 0.00
Market Cap $4.0B
TTM Revenue $0.0
Price / Sales N/A
ROE -50.3%

Historical Factor Score Progression

Held D+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.7) C+ (2.8) D+ (1.6) F (0.0) D+ (1.7)
2026-11-08 C+ (2.5) D+ (1.7) C+ (2.8) D+ (1.6) F (0.0) D+ (1.7)
2026-11-01 C+ (2.5) D+ (1.6) C+ (2.5) D+ (1.6) F (0.0) D+ (1.6)
2026-10-25 C+ (2.5) D+ (1.6) C+ (2.5) D (1.4) F (0.0) D+ (1.6)
2026-10-18 C+ (2.5) D+ (1.6) C+ (2.5) C- (2.1) F (0.0) D+ (1.7)
Page 1 of 5